Quidel Corp
Chiusa
10.61 -16.98
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
10.61
Massimo
11.1
Entrata | -1.1M -93M |
|---|---|
Vendite | 11M 631M |
Margine di Profitto | -14.725 |
Dipendenti | 6,500 |
EBITDA | 86M |
Raccomandazioni | Neutrale |
|---|---|
Previsioni per 12 mesi | +12.15% upside |
Capitalizzazione di Mercato | 129M 847M |
|---|---|
Apertura precedente | 27.59 |
Chiusura precedente | 10.61 |
Quidel Corp Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Notizie correlate
Confronto tra pari
Modifica del prezzo
Quidel Corp Previsione
Obiettivo di Prezzo
By TipRanks
12.15% in crescita
Previsioni per 12 mesi
Media 12 USD 12.15%
Alto 12 USD
Basso 12 USD
Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Quidel Corp - Dist negli ultimi 3 mesi.
Notizie finanziarie
Spese di vendita e di amministrazione
Utile prima delle imposte
Vendite
Costo delle vendite
Utile lordo sulle vendite
Interessi passivi sul debito
EBITDA
Utile operativo
$
Chi Siamo Quidel Corp
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
